[
  {
    "ts": null,
    "headline": "Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment",
    "summary": "Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.",
    "url": "https://finnhub.io/api/news?id=25a4a09bb9b30921d3e256bb6f0d7482eb1a5f4b1f4bedfdcc31a0b21f76fac2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732659390,
      "headline": "Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment",
      "id": 131654555,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.",
      "url": "https://finnhub.io/api/news?id=25a4a09bb9b30921d3e256bb6f0d7482eb1a5f4b1f4bedfdcc31a0b21f76fac2"
    }
  },
  {
    "ts": null,
    "headline": "Invesco American Franchise Fund Q3 2024 Commentary",
    "summary": "Invesco American Franchise Fund currently favors a balance of high quality companies with resilient growth and early cyclical companies with potential to benefit from lower interest rates.",
    "url": "https://finnhub.io/api/news?id=a0a53752da817cd91eeb9a3adcc1d8ca9f7f56ea34d728cc416e1dafc74310d6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732657020,
      "headline": "Invesco American Franchise Fund Q3 2024 Commentary",
      "id": 131655629,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/682049968/image_682049968.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Invesco American Franchise Fund currently favors a balance of high quality companies with resilient growth and early cyclical companies with potential to benefit from lower interest rates.",
      "url": "https://finnhub.io/api/news?id=a0a53752da817cd91eeb9a3adcc1d8ca9f7f56ea34d728cc416e1dafc74310d6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?",
    "summary": "Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a buy?",
    "url": "https://finnhub.io/api/news?id=90d8ab6a663f1a994b23b9c09a625d8f05ca9331088afe822a86415b9c96b7a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732649022,
      "headline": "Eli Lilly Pops After Biden Proposes Medicare Cover Obesity Drugs. Is Lilly Stock A Buy?",
      "id": 131652333,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock popped on news President Joe Biden proposed Medicare and Medicaid pay for weight-loss drugs. Is LLY stock a buy?",
      "url": "https://finnhub.io/api/news?id=90d8ab6a663f1a994b23b9c09a625d8f05ca9331088afe822a86415b9c96b7a8"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Says White House Obesity Plan Is Step in Right Direction",
    "summary": "Novo Nordisk CFO Karsten Knudsen said in an interview that the company is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that it is too early to say how the plans might be affected by the incoming Trump administration.",
    "url": "https://finnhub.io/api/news?id=4b72e25f080e5dc4848012ca636b2e302bdc4c47a4aa4535bf17125765def157",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732648680,
      "headline": "Novo Nordisk Says White House Obesity Plan Is Step in Right Direction",
      "id": 131655522,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk CFO Karsten Knudsen said in an interview that the company is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that it is too early to say how the plans might be affected by the incoming Trump administration.",
      "url": "https://finnhub.io/api/news?id=4b72e25f080e5dc4848012ca636b2e302bdc4c47a4aa4535bf17125765def157"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Climbs 5% as White House Backs Medicare Obesity Drug Proposal",
    "summary": "Obesity Drugs Like Ozempic and Wegovy May Soon Be Covered by Medicare, Sparking Stock Gains",
    "url": "https://finnhub.io/api/news?id=60c543de9954a328d667a9a8c31b36648ba4d17ca428717e0608ff3e8ceccf3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732648310,
      "headline": "Eli Lilly Stock Climbs 5% as White House Backs Medicare Obesity Drug Proposal",
      "id": 131655523,
      "image": "https://s.yimg.com/ny/api/res/1.2/oKDjgOl6d9bMGwW6bjbdNA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD01NTY-/https://media.zenfs.com/en/us.finance.gurufocus/8b34282df3e337e017d4d48d8d2bb143",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Obesity Drugs Like Ozempic and Wegovy May Soon Be Covered by Medicare, Sparking Stock Gains",
      "url": "https://finnhub.io/api/news?id=60c543de9954a328d667a9a8c31b36648ba4d17ca428717e0608ff3e8ceccf3d"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Tuesday Afternoon",
    "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index adding 0.",
    "url": "https://finnhub.io/api/news?id=4aa39c26dea4eda3892b45101a8c58592859abb1f0f54de9ce883f5afba88cd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732646977,
      "headline": "Sector Update: Health Care Stocks Advance Tuesday Afternoon",
      "id": 131655524,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index adding 0.",
      "url": "https://finnhub.io/api/news?id=4aa39c26dea4eda3892b45101a8c58592859abb1f0f54de9ce883f5afba88cd3"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Up as Ely Lilly Rallies on Medicare Proposal -- Health Care Roundup",
    "summary": "Health Care Up as Ely Lilly Rallies on Medicare Proposal -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=c4f9bad9d0aa0b67e780017479c9151a23096e3b3b7637ab898a8f185a6ce8e8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732643220,
      "headline": "Health Care Up as Ely Lilly Rallies on Medicare Proposal -- Health Care Roundup",
      "id": 131774958,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Health Care Up as Ely Lilly Rallies on Medicare Proposal -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=c4f9bad9d0aa0b67e780017479c9151a23096e3b3b7637ab898a8f185a6ce8e8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs",
    "summary": "Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including Medicare and Medicaid.",
    "url": "https://finnhub.io/api/news?id=3a6b3bbba4af6e7cd610874cf90f367808b94afdb7d2bd7f2d57a41b8c8715e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732643056,
      "headline": "Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs",
      "id": 131652338,
      "image": "https://www.investopedia.com/thmb/urfzLsREVeqR7egbD47qzBhmI54=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2161043945-0728ca507d5e45859acdabeec55d352e.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans including Medicare and Medicaid.",
      "url": "https://finnhub.io/api/news?id=3a6b3bbba4af6e7cd610874cf90f367808b94afdb7d2bd7f2d57a41b8c8715e4"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Health Care Roundup: Market Talk",
    "url": "https://finnhub.io/api/news?id=7c1c784b8c0f01d8a5647e2e7467f2aeb1f9efc2d06d4faa7a53751239d8322a",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732641360,
      "headline": "Health Care Roundup: Market Talk",
      "id": 131774925,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Health Care Roundup: Market Talk",
      "url": "https://finnhub.io/api/news?id=7c1c784b8c0f01d8a5647e2e7467f2aeb1f9efc2d06d4faa7a53751239d8322a"
    }
  },
  {
    "ts": null,
    "headline": "Medicare Could Pay for Wegovy. Don’t Count On It.",
    "summary": "The Biden administration said it would allow the program to pay for GLP-1 anti-obesity drugs, but the Trump administration would have to allow that to happen.",
    "url": "https://finnhub.io/api/news?id=fd356d4f442edb570adf3c5dd84efd0797ac31c5cd9a4d96f1a5678a2fc815fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732633800,
      "headline": "Medicare Could Pay for Wegovy. Don’t Count On It.",
      "id": 131643459,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Biden administration said it would allow the program to pay for GLP-1 anti-obesity drugs, but the Trump administration would have to allow that to happen.",
      "url": "https://finnhub.io/api/news?id=fd356d4f442edb570adf3c5dd84efd0797ac31c5cd9a4d96f1a5678a2fc815fa"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.",
    "summary": "The pharmaceutical company's MariTide treatment performs well in a phase 2 study but not as well as Wall Street expected.",
    "url": "https://finnhub.io/api/news?id=47b7084b776006df8e5efa828620d88406041fdd1c5ab7bbc2c3f752e365faec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732633440,
      "headline": "Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.",
      "id": 131643460,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharmaceutical company's MariTide treatment performs well in a phase 2 study but not as well as Wall Street expected.",
      "url": "https://finnhub.io/api/news?id=47b7084b776006df8e5efa828620d88406041fdd1c5ab7bbc2c3f752e365faec"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: MariTide Underwhelms, But There Are Ways To Win",
    "summary": "Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.",
    "url": "https://finnhub.io/api/news?id=e675d5c22ba1ea503e4682d6afacf863c2ac54b08fcfb4811b0184c18ee778b6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732633388,
      "headline": "Amgen: MariTide Underwhelms, But There Are Ways To Win",
      "id": 131651601,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162809200/image_2162809200.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.",
      "url": "https://finnhub.io/api/news?id=e675d5c22ba1ea503e4682d6afacf863c2ac54b08fcfb4811b0184c18ee778b6"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound",
    "summary": "Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.",
    "url": "https://finnhub.io/api/news?id=5df8a67b59425c336a9abd799ab47832f17fe00781844cda2ba9ecd53aa9a5f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732632870,
      "headline": "Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's Zepbound",
      "id": 131643462,
      "image": "https://media.zenfs.com/en/ibd.com/dc395bd727f94e9cc6914b25d707ad7a",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.",
      "url": "https://finnhub.io/api/news?id=5df8a67b59425c336a9abd799ab47832f17fe00781844cda2ba9ecd53aa9a5f9"
    }
  },
  {
    "ts": null,
    "headline": "Biden Proposes Medicare, Medicaid Coverage of Obesity Drugs",
    "summary": "(Bloomberg) -- The Biden administration is proposing a rule that would require the US government to cover weight-loss drugs, potentially expanding access for millions of Americans with obesity and creating a huge new medical bill for President-elect Donald Trump.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets His",
    "url": "https://finnhub.io/api/news?id=2111eecec2bcefd930f4a0bdd01f62fcd9f86485746944efeffd39c19575222d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732630585,
      "headline": "Biden Proposes Medicare, Medicaid Coverage of Obesity Drugs",
      "id": 131636577,
      "image": "https://s.yimg.com/ny/api/res/1.2/lY0NOgr.ghWsOi7l0CMBjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/2050b6ca0b20c0cb0ca9df47cb599b59",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- The Biden administration is proposing a rule that would require the US government to cover weight-loss drugs, potentially expanding access for millions of Americans with obesity and creating a huge new medical bill for President-elect Donald Trump.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets His",
      "url": "https://finnhub.io/api/news?id=2111eecec2bcefd930f4a0bdd01f62fcd9f86485746944efeffd39c19575222d"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Falls as Weight-Loss Shot  Results Disappoint Street",
    "summary": "(Bloomberg) -- Amgen Inc. shares fell the most in 23 years after its experimental obesity shot failed to outperform those of rivals and showed a high rate of side effects.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets Historic Push for 80,000 Homes With $5 Billion PledgeThe reaction shows how high the bar is for",
    "url": "https://finnhub.io/api/news?id=46459a8f1bdb79e32f7a70432875bbef3a492b7242cebd9b1235aeda2eb66aef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732631920,
      "headline": "Amgen Falls as Weight-Loss Shot  Results Disappoint Street",
      "id": 131643464,
      "image": "https://s.yimg.com/ny/api/res/1.2/J1C3rZnBRECLRjxOrGLO.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/bloomberg_markets_842/4f42fa846d08ca07e91a458445768199",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Amgen Inc. shares fell the most in 23 years after its experimental obesity shot failed to outperform those of rivals and showed a high rate of side effects.Most Read from BloombergNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldNYC's Underground Steam System May Be Key to a Greener FutureNYC Gets Historic Push for 80,000 Homes With $5 Billion PledgeThe reaction shows how high the bar is for",
      "url": "https://finnhub.io/api/news?id=46459a8f1bdb79e32f7a70432875bbef3a492b7242cebd9b1235aeda2eb66aef"
    }
  },
  {
    "ts": null,
    "headline": "Amgen shows 20% weight loss in once-monthly injectable MariTide",
    "summary": "Amgen's latest once-monthly weight loss drug data looks \"OK,\" analysts say, as its path to approval still remains murky.",
    "url": "https://finnhub.io/api/news?id=fc9241ad543c19d15f2478738235cd11fd04e617fa2164d7fdf66fb884310f66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732630617,
      "headline": "Amgen shows 20% weight loss in once-monthly injectable MariTide",
      "id": 131636575,
      "image": "https://s.yimg.com/ny/api/res/1.2/qPrurmHpj6AEFYfe5D4gJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2024-09/40d85280-7b7a-11ef-be67-e5cf7ffe12b0",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen's latest once-monthly weight loss drug data looks \"OK,\" analysts say, as its path to approval still remains murky.",
      "url": "https://finnhub.io/api/news?id=fc9241ad543c19d15f2478738235cd11fd04e617fa2164d7fdf66fb884310f66"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Health Care Fund Q3 2024 Commentary",
    "summary": "Invesco Health Care Fund underperformed its benchmark. Despite earlier signs of improving trends, our health care outlook is bearish. Read more here.",
    "url": "https://finnhub.io/api/news?id=8811a159dd6bae05dcf408a9f48cd5d03a26ef619260c992cad970093f4bc185",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732624620,
      "headline": "Invesco Health Care Fund Q3 2024 Commentary",
      "id": 131646502,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Invesco Health Care Fund underperformed its benchmark. Despite earlier signs of improving trends, our health care outlook is bearish. Read more here.",
      "url": "https://finnhub.io/api/news?id=8811a159dd6bae05dcf408a9f48cd5d03a26ef619260c992cad970093f4bc185"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Obesity Drug Cut Weight In Closely Watched Study",
    "summary": "A highly anticipated obesity-drug candidate from biotech  Amgen  helped patients shed a significant amount of weight in a midstage study.  Subjects taking Amgen’s MariTide lost 20% of their body weight compared with those who received placebos, Amgen said Tuesday.  Analysts had generally expected the drug to achieve weight reduction of 20% or more.",
    "url": "https://finnhub.io/api/news?id=8a0d16aaa6995e198f7435caf98cb20babfdcde9e04af972b02869946c0b9ce7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732624440,
      "headline": "Amgen Obesity Drug Cut Weight In Closely Watched Study",
      "id": 131643468,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A highly anticipated obesity-drug candidate from biotech  Amgen  helped patients shed a significant amount of weight in a midstage study.  Subjects taking Amgen’s MariTide lost 20% of their body weight compared with those who received placebos, Amgen said Tuesday.  Analysts had generally expected the drug to achieve weight reduction of 20% or more.",
      "url": "https://finnhub.io/api/news?id=8a0d16aaa6995e198f7435caf98cb20babfdcde9e04af972b02869946c0b9ce7"
    }
  },
  {
    "ts": null,
    "headline": "Update: Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs",
    "summary": "(Updates with a statement from Eli Lilly in the seventh paragraph.",
    "url": "https://finnhub.io/api/news?id=8787cc99c25ba51f9432f5494fc596414231176d6d3290a130a7157f20286fd7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732622790,
      "headline": "Update: Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs",
      "id": 131636585,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Updates with a statement from Eli Lilly in the seventh paragraph.",
      "url": "https://finnhub.io/api/news?id=8787cc99c25ba51f9432f5494fc596414231176d6d3290a130a7157f20286fd7"
    }
  },
  {
    "ts": null,
    "headline": "Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark",
    "summary": "Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.",
    "url": "https://finnhub.io/api/news?id=6c6a172ed46de1b12f44d5aa35f12f5414590f9a4ef91ba7cbd4a0dffccbf278",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732621200,
      "headline": "Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark",
      "id": 131655538,
      "image": "https://imgproxy.divecdn.com/2t--Zw5F8Af5zATrL7R6DAG6mhfi2YJrC14PGntAqLg/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDE4MzI0MzQ5XzEuanBn.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.",
      "url": "https://finnhub.io/api/news?id=6c6a172ed46de1b12f44d5aa35f12f5414590f9a4ef91ba7cbd4a0dffccbf278"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Charter Fund Q3 2024 Commentary",
    "summary": "The Invesco Charter Fundâs Class A shares at NAV returned 5.37% for Q3 2024, underperforming the Russell 1000 Index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=827ba3456ae87f9e272d78455907937af12e18fe74c271e84b307d2438ae7a90",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732617900,
      "headline": "Invesco Charter Fund Q3 2024 Commentary",
      "id": 131639675,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205518/image_1322205518.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Invesco Charter Fundâs Class A shares at NAV returned 5.37% for Q3 2024, underperforming the Russell 1000 Index. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=827ba3456ae87f9e272d78455907937af12e18fe74c271e84b307d2438ae7a90"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk, Eli Lilly shares up as Biden proposes obesity coverage",
    "summary": "STORY: Novo Nordisk and Eli Lilly shares rose on Tuesday . Investors were excited as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare...",
    "url": "https://finnhub.io/api/news?id=9c0cffdf5a8e38332de706a674f322f47edb6f7fb3f46a2704f03452fea662a6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732617007,
      "headline": "Novo Nordisk, Eli Lilly shares up as Biden proposes obesity coverage",
      "id": 131639837,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "STORY: Novo Nordisk and Eli Lilly shares rose on Tuesday . Investors were excited as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare...",
      "url": "https://finnhub.io/api/news?id=9c0cffdf5a8e38332de706a674f322f47edb6f7fb3f46a2704f03452fea662a6"
    }
  },
  {
    "ts": null,
    "headline": "White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs",
    "summary": "More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.",
    "url": "https://finnhub.io/api/news?id=9134d813dd02d6ceedbb8a3a7ef7a15b3d3cd278b78cdf3304691d3491a986a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732617000,
      "headline": "White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs",
      "id": 131643473,
      "image": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the proposal.",
      "url": "https://finnhub.io/api/news?id=9134d813dd02d6ceedbb8a3a7ef7a15b3d3cd278b78cdf3304691d3491a986a0"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.",
    "summary": "Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.",
    "url": "https://finnhub.io/api/news?id=e7302089422895c4eb7a4cb09b28e8a6dd435e5c1f542d55c404a5b96eba88f6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732612500,
      "headline": "Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.",
      "id": 131635985,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.",
      "url": "https://finnhub.io/api/news?id=e7302089422895c4eb7a4cb09b28e8a6dd435e5c1f542d55c404a5b96eba88f6"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi joins J&J, Eli Lilly in proposing 340B rebate model",
    "summary": "Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how regulators will react.",
    "url": "https://finnhub.io/api/news?id=e2c65ac9a348b840b930a39a7012da58ed464b06cd0a27aa83990a0910bc9bc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732611780,
      "headline": "Sanofi joins J&J, Eli Lilly in proposing 340B rebate model",
      "id": 131643474,
      "image": "https://imgproxy.divecdn.com/sJde9s13htXdbDYTH8JFwHQXqK8elE4ovKg0CluPAZ8/g:nowe:0:87/c:520:294/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDE4OTA3MTU1XzEuanBn.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how regulators will react.",
      "url": "https://finnhub.io/api/news?id=e2c65ac9a348b840b930a39a7012da58ed464b06cd0a27aa83990a0910bc9bc3"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test",
    "summary": "Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test",
    "url": "https://finnhub.io/api/news?id=96eee396a6af32f7101047b8642516f464257cb0e026598ae460ce7adc01ab71",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732611270,
      "headline": "Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test",
      "id": 131635960,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test",
      "url": "https://finnhub.io/api/news?id=96eee396a6af32f7101047b8642516f464257cb0e026598ae460ce7adc01ab71"
    }
  },
  {
    "ts": null,
    "headline": "Weight-loss-drug makers’ stocks get a boost from new Biden coverage proposal, but will it hold up?",
    "summary": "Weight-loss-drug makers’ stocks get a boost from new Biden coverage proposal, but will it hold up?",
    "url": "https://finnhub.io/api/news?id=499b931f07c8b7575ffde3cff20f7b83344dccaf9101afda24cb1b8ed3bc6696",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732609200,
      "headline": "Weight-loss-drug makers’ stocks get a boost from new Biden coverage proposal, but will it hold up?",
      "id": 131635986,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Weight-loss-drug makers’ stocks get a boost from new Biden coverage proposal, but will it hold up?",
      "url": "https://finnhub.io/api/news?id=499b931f07c8b7575ffde3cff20f7b83344dccaf9101afda24cb1b8ed3bc6696"
    }
  },
  {
    "ts": null,
    "headline": "Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?",
    "summary": "Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?",
    "url": "https://finnhub.io/api/news?id=d4afc9ee7e74c1fac9babb94c2d21dc405b024fe54866aae7df2331498ce4f43",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732605248,
      "headline": "Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?",
      "id": 131635987,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Weight-loss stocks get a boost from new Biden proposal on drug coverage, but will it hold up?",
      "url": "https://finnhub.io/api/news?id=d4afc9ee7e74c1fac9babb94c2d21dc405b024fe54866aae7df2331498ce4f43"
    }
  },
  {
    "ts": null,
    "headline": "Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans",
    "summary": "Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans",
    "url": "https://finnhub.io/api/news?id=013bd1f1f1f0950ebe72b0dde1b67a6114a35eda80fd7a021b3f203ad20b0208",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732600380,
      "headline": "Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans",
      "id": 131635988,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans",
      "url": "https://finnhub.io/api/news?id=013bd1f1f1f0950ebe72b0dde1b67a6114a35eda80fd7a021b3f203ad20b0208"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals",
    "summary": "Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future growth despite investor concerns.",
    "url": "https://finnhub.io/api/news?id=fd226f15a67885f3c8f83cd855379f75c3e75e36b48e957338d8fbbc61304321",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732594827,
      "headline": "Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals",
      "id": 131630055,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367176250/image_1367176250.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future growth despite investor concerns.",
      "url": "https://finnhub.io/api/news?id=fd226f15a67885f3c8f83cd855379f75c3e75e36b48e957338d8fbbc61304321"
    }
  }
]